Skelaxin Pay-For-Delay Battle Heads To Pa. State Court

Law360, Philadelphia (November 7, 2012, 4:03 PM EST) -- The latest front in the ongoing antitrust dispute over the muscle relaxant Skelaxin opened in Pennsylvania state court Monday as the head of SigmaPharm Inc. accused a Pfizer unit of conspiring with a Mutual Pharmaceutical Co. Inc. executive to keep generic forms of the drug off the market.

Spiridon Spireas accused Mutual executive Richard Roberts of conspiring with King Pharmaceuticals Inc., which is now owned by Pfizer, in 2005 to derail abbreviated new drug applications pending before the U.S. Food and Drug Administration that would have...
To view the full article, register now.